HOXB7 can be targeted indirectly via MEK/ERK inhibition or more directly through HOX/PBX interaction inhibitors such as HXR9, which has shown preclinical anti-tumor efficacy in other HOX-driven cancers (32). The gene discussed is MAP2K7; the disease is neoplasm.